XML 46 R21.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Stockholders' Equity | 9 Months Ended
--- | ---
Sep. 30, 2022
Compensation Related Costs [Abstract] |
Stockholders' Deficit | Changes in Stockholders’ Equity (Deficit) The following tables present certain information regarding our stockholders’ equity (deficit) as of September 30, 2022 and 2021:
| Nine Months Ended September 30, 2022
| Common Stock |  | Additional Paid in Capital |  | Retained Earnings (Accumulated Loss) |  | Treasury Stock |  | Accumulated Other Comprehensive Loss |  | Noncontrolling Interest |  | Total
January 1, 2022 | $ | 1 |  |  | $ | 1,337 |  |  | $ | (3,158) |  |  | $ | (175) |  |  | $ | (261) |  |  | $ | 150 |  |  | $ | (2,106) |
Settlement of liability awards and other, net | — |  |  | 43 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 43 |
Vesting of RSUs, net of tax withholdings | — |  |  | (31) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (31) |
Purchase of treasury stock | — |  |  | — |  |  | — |  |  | (51) |  |  | — |  |  | — |  |  | (51) |
Stock-based compensation | — |  |  | 17 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 17 |
Net income | — |  |  | — |  |  | 26 |  |  | — |  |  | — |  |  | 2 |  |  | 28 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (37) |  |  | — |  |  | (37) |
March 31, 2022 | $ | 1 |  |  | $ | 1,366 |  |  | $ | (3,132) |  |  | $ | (226) |  |  | $ | (298) |  |  | $ | 152 |  |  | $ | (2,137) |
Vesting of RSUs, net of tax withholdings and other | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Purchase of treasury stock | — |  |  | — |  |  | — |  |  | (152) |  |  | — |  |  | — |  |  | (152) |
Purchase of SciPlay common stock | — |  |  | (6) |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | (7) |
Stock-based compensation | — |  |  | 15 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 15 |
Net income | — |  |  | — |  |  | 3,291 |  |  | — |  |  | — |  |  | 4 |  |  | 3,295 |
Other comprehensive loss(1) | — |  |  | — |  |  | — |  |  | — |  |  | (48) |  |  | — |  |  | (48) |
June 30, 2022 | $ | 1 |  |  | $ | 1,375 |  |  | $ | 159 |  |  | $ | (378) |  |  | $ | (346) |  |  | $ | 155 |  |  | $ | 966 |
Vesting of RSUs, net of tax withholdings and other | — |  |  | (3) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (3) |
Purchase of SciPlay common stock | — |  |  | (10) |  |  | — |  |  | — |  |  | — |  |  | (1) |  |  | (11) |
Stock-based compensation | — |  |  | 14 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 14 |
Net income | — |  |  | — |  |  | 328 |  |  | — |  |  | — |  |  | 7 |  |  | 335 |
Other comprehensive loss(1) | — |  |  | — |  |  | — |  |  | — |  |  | (69) |  |  | — |  |  | (69) |
September 30, 2022 | $ | 1 |  |  | $ | 1,376 |  |  | $ | 487 |  |  | $ | (378) |  |  | $ | (415) |  |  | $ | 161 |  |  | $ | 1,232 |
(1) Includes reclassifications of $51 million and $74 million for the three and nine months ended September 30, 2022, respectively, from accumulated other comprehensive loss into income due to the sales of discontinued operations (see Note 2).
| Nine Months Ended September 30, 2021
| Common Stock |  | Additional Paid in Capital |  | Accumulated Loss |  | Treasury Stock |  | Accumulated Other Comprehensive Loss |  | Noncontrolling Interest |  | Total
January 1, 2021 | $ | 1 |  |  | $ | 1,268 |  |  | $ | (3,529) |  |  | $ | (175) |  |  | $ | (218) |  |  | $ | 129 |  |  | $ | (2,524) |
Vesting of RSUs, net of tax withholdings and other | — |  |  | (13) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (13) |
Stock-based compensation | — |  |  | 17 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 17 |
Net (loss) income | — |  |  | — |  |  | (15) |  |  | — |  |  | — |  |  | 6 |  |  | (9) |
Other comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | 8 |  |  | — |  |  | 8 |
March 31, 2021 | $ | 1 |  |  | $ | 1,272 |  |  | $ | (3,544) |  |  | $ | (175) |  |  | $ | (210) |  |  | $ | 135 |  |  | $ | (2,521) |
Vesting of RSUs, net of tax withholdings and other | — |  |  | (4) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (4) |
Stock-based compensation | — |  |  | 31 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 31 |
Net income | — |  |  | — |  |  | 109 |  |  | — |  |  | — |  |  | 4 |  |  | 113 |
Other comprehensive income | — |  |  | — |  |  | — |  |  | — |  |  | 11 |  |  | — |  |  | 11 |
June 30, 2021 | $ | 1 |  |  | $ | 1,299 |  |  | $ | (3,435) |  |  | $ | (175) |  |  | $ | (199) |  |  | $ | 139 |  |  | $ | (2,370) |
Vesting of RSUs, net of tax withholdings and other | — |  |  | (3) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (3) |
Stock-based compensation | — |  |  | 22 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 22 |
Net income | — |  |  | — |  |  | 182 |  |  | — |  |  | — |  |  | 5 |  |  | 187 |
Other comprehensive loss | — |  |  | — |  |  | — |  |  | — |  |  | (27) |  |  | — |  |  | (27) |
September 30, 2021 | $ | 1 |  |  | $ | 1,318 |  |  | $ | (3,253) |  |  | $ | (175) |  |  | $ | (226) |  |  | $ | 144 |  |  | $ | (2,191) |
Stock Based Compensation The following reflects total stock-based compensation expense recognized under all programs in our continuing operations:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Related to L&W stock options | $ | — |  |  | $ | 3 |  |  | $ | 1 |  |  | $ | 25 |
Related to L&W RSUs | 12 |  |  | 23 |  |  | 39 |  |  | 51 |
Related to SciPlay RSUs | 3 |  |  | — |  |  | 7 |  |  | 5 |
Total | $ | 15 |  |  | $ | 26 |  |  | $ | 47 |  |  | $ | 81 |
Restricted Stock Units A summary of the changes in RSUs outstanding under our equity-based compensation plans during the nine months ended September 30, 2022 is presented below:
| Number of Restricted Stock Units |  | Weighted Average Grant Date Fair Value
Unvested RSUs as of December 31, 2021 | 2.7 |  |  | $ | 32.03 |
Granted | 1.7 |  |  | $ | 57.26 |
Vested | (1.9) |  |  | $ | 38.75 |
Cancelled | (0.7) |  |  | $ | 37.75 |
Unvested RSUs as of September 30, 2022 | 1.8 |  |  | $ | 46.50 |
The weighted-average grant date fair value of RSUs granted during the nine months ended September 30, 2022 and 2021 was $57.26 and $55.01, respectively. The fair value of each RSU grant is based on the market value of our common stock at the time of grant. As of September 30, 2022, we had $54 million in total unrecognized stock-based compensation expense relating to unvested RSUs that will be amortized over a weighted-average period of approximately two years. The fair value at vesting date of RSUs vested during the nine months ended September 30, 2022 and 2021 was $71.6 million and $74.1 million, respectively. Share Repurchase Programs As described in Note 17 within our 2021 10-K and in our Current Report on Form 8-K filed with the SEC on March 1, 2022, our Board of Directors approved a share repurchase program under which the Company is authorized to repurchase, from time to time through February 25, 2025, up to an aggregate amount of $750 million of our outstanding common stock. During the nine months ended September 30, 2022, we repurchased 3.7 million shares of common stock under the program at an aggregate cost of $203 million and an average of $55.39 per share. Subsequent to September 30, 2022 and through November 4, 2022, we purchased an additional 0.7 million shares of common stock at an aggregate cost of $38 million. On May 9, 2022, SciPlay’s Board of Directors approved a share repurchase program under which it is authorized to repurchase, from time to time through May 9, 2024, up to an aggregate amount of $60 million of its outstanding Class A common stock. During the nine months ended September 30, 2022, SciPlay repurchased 1.4 million shares of Class A common stock under the program at an aggregate cost of $18 million and an average of $13.13 per share. Subsequent to September 30, 2022 and through November 4, 2022, SciPlay purchased an additional 0.7 million shares of common stock at an aggregate cost of $10 million.

X
- References No definition available. + Details
Name: | us-gaap_CompensationRelatedCostsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 710 -URI https://asc.fasb.org/topic&trid=2127225 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6409950&loc=d3e20396-108366 + Details
Name: | us-gaap_CompensationRelatedCostsGeneralTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration